MedPath

Salsalate

Generic Name
Salsalate
Drug Type
Small Molecule
Chemical Formula
C14H10O5
CAS Number
552-94-3
Unique Ingredient Identifier
V9MO595C9I
Background

Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.

Indication

For relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.

A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy

Phase 1
Completed
Conditions
Progressive Supranuclear Palsy
Interventions
First Posted Date
2015-04-21
Last Posted Date
2021-04-01
Lead Sponsor
Adam Boxer
Target Recruit Count
10
Registration Number
NCT02422485
Locations
🇺🇸

OHSU Parkinson Center & Movement Disorder Program, Portland, Oregon, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

Not Applicable
Completed
Conditions
Hypertension
Diabetes
Interventions
First Posted Date
2015-04-02
Last Posted Date
2019-01-08
Lead Sponsor
Emory University
Target Recruit Count
36
Registration Number
NCT02406586
Locations
🇺🇸

Grady Memorial Hospital, Atlanta, Georgia, United States

Using Salsalate to Target Adipocyte Macrophage Infiltration

Phase 1
Completed
Conditions
Diabetes Risk
Interventions
Drug: Placebo (4 g/day)
First Posted Date
2014-05-05
Last Posted Date
2014-05-05
Lead Sponsor
University of Southern California
Target Recruit Count
30
Registration Number
NCT02130804
Locations
🇺🇸

University of Southern California, Clinical Trials Unit (CTU), Los Angeles, California, United States

🇺🇸

University of Southern California Diabetes Obesity Research Institute (DORI), Los Angeles, California, United States

Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?

Not Applicable
Completed
Conditions
Pre Diabetes
Insulin Resistant
Interventions
Drug: Placebo
First Posted Date
2013-12-11
Last Posted Date
2016-05-05
Lead Sponsor
Stanford University
Target Recruit Count
41
Registration Number
NCT02007577
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Inflammation Inhibition in Prediabetic Humans

Phase 2
Terminated
Conditions
Obese
Prediabetes
Interventions
Drug: Placebo
First Posted Date
2013-11-06
Last Posted Date
2023-09-11
Lead Sponsor
Gary L. Pierce
Target Recruit Count
21
Registration Number
NCT01977417
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

Targeting Inflammation to Treat Cardiovascular Aging

Phase 2
Completed
Conditions
Vascular Stiffness
Endothelial Dysfunction
Diastolic Dysfunction
Interventions
Drug: Placebo (for salsalate)
First Posted Date
2013-01-25
Last Posted Date
2018-05-31
Lead Sponsor
Gary L. Pierce
Target Recruit Count
59
Registration Number
NCT01775865
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

A Study of CAT-1004 Biomarkers in Healthy Subjects

Phase 1
Completed
Conditions
Assessment of Mechanistic Blood Biomarkers in Healthy Humans
Interventions
First Posted Date
2012-08-22
Last Posted Date
2012-10-30
Lead Sponsor
Catabasis Pharmaceuticals
Target Recruit Count
9
Registration Number
NCT01670773
Locations
🇺🇸

ProMedica, Brighton, Massachusetts, United States

Salsalate as an Adjunctive Treatment for Patients With Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
Interventions
First Posted Date
2012-04-17
Last Posted Date
2018-05-08
Lead Sponsor
University of Massachusetts, Worcester
Target Recruit Count
17
Registration Number
NCT01578486
Locations
🇺🇸

University of Massaschusetts Medical School, Worcester, Massachusetts, United States

Trial To Evaluate the Efficacy of Oral Salsalate in the Treatment of Older Adults With Unexplained Anemia

Phase 2
Terminated
Conditions
Anemia
Interventions
Drug: Placebo
First Posted Date
2012-01-10
Last Posted Date
2016-10-18
Lead Sponsor
Harvey Jay Cohen
Target Recruit Count
11
Registration Number
NCT01506726
Locations
🇺🇸

Johns Hopkins University Geriatrics Center, Baltimore, Maryland, United States

🇺🇸

Lakeview Medical Research, Summerfield, Florida, United States

🇺🇸

St Joseph's/Candler Health System, Savannah, Georgia, United States

and more 7 locations

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

Phase 1
Terminated
Conditions
Polycystic Ovary Syndrome
Interventions
First Posted Date
2011-12-09
Last Posted Date
2017-02-10
Lead Sponsor
Indiana University
Target Recruit Count
47
Registration Number
NCT01489319
Locations
🇺🇸

Indiana University Hospital, Indianapolis, Indiana, United States

© Copyright 2025. All Rights Reserved by MedPath